Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38018349)

  • 21. Size-tunable nanogels for cascaded release of metronidazole and chemotherapeutic agents to combat Fusobacterium nucleatum-infected colorectal cancer.
    Xie S; Wei L; Liu Y; Meng J; Cao W; Qiu B; Li X
    J Control Release; 2024 Jan; 365():16-28. PubMed ID: 37956925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fusobacterium nucleatum, the communication with colorectal cancer.
    Luo K; Zhang Y; Xv C; Ji J; Lou G; Guo X; Chen M; Zhang Y; Wei H; Guo M; Huang R; Yu S
    Biomed Pharmacother; 2019 Aug; 116():108988. PubMed ID: 31112873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    LaCourse KD; Zepeda-Rivera M; Kempchinsky AG; Baryiames A; Minot SS; Johnston CD; Bullman S
    Cell Rep; 2022 Nov; 41(7):111625. PubMed ID: 36384132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In situ-activated photothermal nanoplatform for on-demand NO gas delivery and enhanced colorectal cancer treatment.
    Xin Y; Yu Y; Su M; Li X; Elsabahy M; Gao H
    J Control Release; 2023 Jul; 359():69-84. PubMed ID: 37245723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of Intratumoral
    Qu X; Yin F; Pei M; Chen Q; Zhang Y; Lu S; Zhang X; Liu Z; Li X; Chen H; Zhang Y; Qin H
    ACS Nano; 2023 Jun; 17(12):11466-11480. PubMed ID: 37201179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Both endogenous and exogenous miR-139-5p inhibit Fusobacterium nucleatum-related colorectal cancer development.
    Zhao Y; Tao Q; Li S; Zheng P; Liu J; Liang X
    Eur J Pharmacol; 2020 Dec; 888():173459. PubMed ID: 32768506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin abrogates Fusobacterium nucleatum-induced chemoresistance in colorectal cancer by inhibiting miR-361-5p/sonic hedgehog signaling-regulated stemness.
    Hong XL; Yu TC; Huang XW; Wang JL; Sun TT; Yan TT; Zhou CB; Chen HM; Su WY; Du W; Xiong H
    Br J Cancer; 2023 Jan; 128(2):363-374. PubMed ID: 36396820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fusobacterium nucleatum and colorectal cancer: A mechanistic overview.
    Hashemi Goradel N; Heidarzadeh S; Jahangiri S; Farhood B; Mortezaee K; Khanlarkhani N; Negahdari B
    J Cell Physiol; 2019 Mar; 234(3):2337-2344. PubMed ID: 30191984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Analysis of Colon Cancer-Derived Fusobacterium nucleatum Subspecies: Inflammation and Colon Tumorigenesis in Murine Models.
    Queen J; Domingue JC; White JR; Stevens C; Udayasuryan B; Nguyen TTD; Wu S; Ding H; Fan H; McMann M; Corona A; Larman TC; Verbridge SS; Housseau F; Slade DJ; Drewes JL; Sears CL
    mBio; 2021 Feb; 13(1):e0299121. PubMed ID: 35130731
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Kim HS; Kim CG; Kim WK; Kim KA; Yoo J; Min BS; Paik S; Shin SJ; Lee H; Lee K; Kim H; Shin EC; Kim TM; Ahn JB
    Front Cell Infect Microbiol; 2023; 13():1101291. PubMed ID: 36960042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance.
    Chen L; Zhao R; Kang Z; Cao Z; Liu N; Shen J; Wang C; Pan F; Zhou X; Liu Z; Yang Y; Chen Q
    J Control Release; 2023 Nov; 363():43-56. PubMed ID: 37734673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Fruits of
    Lin LT; Shi YC; Choong CY; Tai CJ
    Molecules; 2021 Jul; 26(13):. PubMed ID: 34279421
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Chen S; Su T; Zhang Y; Lee A; He J; Ge Q; Wang L; Si J; Zhuo W; Wang L
    Gut Microbes; 2020 May; 11(3):511-525. PubMed ID: 31910722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2.
    Guo P; Tian Z; Kong X; Yang L; Shan X; Dong B; Ding X; Jing X; Jiang C; Jiang N; Yu Y
    J Exp Clin Cancer Res; 2020 Sep; 39(1):202. PubMed ID: 32993749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer.
    Jiang SS; Xie YL; Xiao XY; Kang ZR; Lin XL; Zhang L; Li CS; Qian Y; Xu PP; Leng XX; Wang LW; Tu SP; Zhong M; Zhao G; Chen JX; Wang Z; Liu Q; Hong J; Chen HY; Chen YX; Fang JY
    Cell Host Microbe; 2023 May; 31(5):781-797.e9. PubMed ID: 37130518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target identification in Fusobacterium nucleatum by subtractive genomics approach and enrichment analysis of host-pathogen protein-protein interactions.
    Kumar A; Thotakura PL; Tiwary BK; Krishna R
    BMC Microbiol; 2016 May; 16():84. PubMed ID: 27176600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome.
    Flanagan L; Schmid J; Ebert M; Soucek P; Kunicka T; Liska V; Bruha J; Neary P; Dezeeuw N; Tommasino M; Jenab M; Prehn JH; Hughes DJ
    Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1381-90. PubMed ID: 24599709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer.
    Ramos A; Hemann MT
    Cell; 2017 Jul; 170(3):411-413. PubMed ID: 28753421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer.
    Wang N; Fang JY
    Trends Microbiol; 2023 Feb; 31(2):159-172. PubMed ID: 36058786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between
    Proença MA; Biselli JM; Succi M; Severino FE; Berardinelli GN; Caetano A; Reis RM; Hughes DJ; Silva AE
    World J Gastroenterol; 2018 Dec; 24(47):5351-5365. PubMed ID: 30598580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.